References

  1. Schorge JO. Uterine sarcoma. In: Schorge JO, Schaffer JI, Halvorson LM, Hoffman BL, Bradshaw KD, Cunningham FG, editors. Williams Gynecology. 2008. New York. The McGraw-Hill Companies.

  2. Dorigo O. Annekathryn G. Premalignant & Malignant Disorders of the Uterine Corpus. In: DeCherney AH, Nathan L, Goodwin MT, Laufer N, editors. Current Diagnosis & Treatment Obstetrics & Gynecology, Tenth Edition. 2006. New-York. The McGraw-Hill Companies.

  3. Enow-Orock GE, Nsagha DS, Asson NJ, Doh AS, Muna WFT. Primary sarcomas of the corpus uteri: a clinic pathologic and literature review of 13 cases seen in 5 years in Yaounde, Cameroon. Wudpecker journal of medical Sciences. 2012; 1(3):019-022. PubMed | Google Scholar

  4. Le T. Adjuvant pelvic radiotherapy for uterine Carcinosarcoma in a high risk population. Eur J Surg Oncol. 2001; 27(3):282-5. PubMed | Google Scholar

  5. Kernochan LE, Garcia RL. Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw. 2009; 7(5):550-6. PubMed | Google Scholar

  6. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010; 116(1):131-9. PubMed | Google Scholar

  7. Spacek J, Laco J, Petera J, Jílek P, Krepinská E, Rezác A et al. Prognostic factors of mesenchymal and mixed tumors of uterus. Ceska Gynekol. 2009; 74(4):292. PubMed | Google Scholar

  8. Nam JH. Surgical treatment of uterine sarcoma. Best Pract Res Clin Obstet Gynaecol. 2011; 25(6):751-60. PubMed | Google Scholar

  9. Galaal K, Godfrey K, Naik R, Kucukmetin A, Bryant A. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev. 2013; 2:CD006812. PubMed | Google Scholar

  10. Gerszten K, Faul C, Kounelis S, Huang Q, Kelley J, Jones MW. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol. 1998; 68(1):8-13. PubMed | Google Scholar